[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
A new group of drugs-oestrogen agonists-antagonists (tamoxifen and raloxifen) is discussed. In view of their potentially favourable effects on the bone and lipids and lacking unfavourable action on the uterus and mammary gland, after successful completion of clinical studies, these preparations may be possibly important for the prophylaxis and treatment of osteoporosis.
Hoszowski
K
K
II Oddziału Wewnetrznego Szpitala Kolejowego w Warszawie.
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D004965:Estrogen Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D010880:Piperidines / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride; D013629:Tamoxifen / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D010880:Piperidines; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride
Agoniści-antagoniści estrogenów, ich potencjalne zastosowanie w profilaktyce i leczeniu osteoporozy.